Research Analysts Set Expectations for KROS FY2026 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Equities research analysts at Leerink Partnrs increased their FY2026 earnings per share estimates for shares of Keros Therapeutics in a report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($4.66) per share for the year, up from their […]

Leave a Reply

Your email address will not be published.

Previous post Principal Financial Group Inc. Grows Stock Holdings in Hanmi Financial Co. (NASDAQ:HAFC)
Next post Y Intercept Hong Kong Ltd Acquires Shares of 13,281 Avidity Biosciences, Inc. (NASDAQ:RNA)